Related Experiment Video
Updated: Sep 16, 2025
07:14
A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
Published on: May 31, 2016
14.9K
Disease-Modifying Trials in Treated Parkinson's Disease: "Stable Treated" Does Not Equate with Biological Stability
M Maral Mouradian1, A Jon Stoessl2, Anthony E Lang3
1Robert Wood Johnson Medical School Institute for Neurological Therapeutics, and Department of Neurology, Rutgers Health, Piscataway, New Jersey, USA.
Summary
Clinical trials for Parkinson's disease are shifting to include patients on medication. This review highlights challenges in interpreting results due to medication effects on brain changes and outcomes.
Area of Science:
- Neurology
- Clinical Trial Design
- Pharmacology
Background:
- Traditional Parkinson's disease (PD) trials enroll drug-naïve patients.
- Recent trials enroll PD patients on stable anti-parkinsonian medication.
- Current trial designs lack uniform medication protocols and fail to account for pharmacodynamic changes.
Purpose of the Study:
- To review the impact of dopaminergic therapy on clinical and neuroimaging outcomes in Parkinson's disease trials.
- To identify challenges in interpreting trial results due to medication effects.
Main Methods:
- Literature review of studies on dopaminergic therapy in Parkinson's disease.
- Analysis of the effects of medication on clinical and neuroimaging outcome measures.
- Discussion of challenges in interpreting trial outcomes.
Main Results:
- Dopaminergic therapies, especially levodopa, induce significant pharmacodynamic changes in the parkinsonian brain.
- These medication-induced changes can confound the interpretation of clinical and neuroimaging outcomes.
- Lack of standardized medication regimens complicates outcome assessment.
Conclusions:
- Current trial designs enrolling medicated Parkinson's disease patients face interpretation challenges.
- Understanding medication effects is crucial for accurate assessment of disease-modifying therapies.
- Future trial designs must account for dopaminergic therapy's impact on outcomes.
Related Concept Videos
01:24Parkinson's Disease: Treatment
389
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389
01:15Parkinson's Disease: Overview
716
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
716
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:37Neural Regulation
40.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.3K
01:11Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
01:16Clinical Trials
8.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.6K